Kabra Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE323K01017
  • NSEID:
  • BSEID: 524322
INR
18.61
-0.97 (-4.95%)
BSENSE

Nov 20

BSE+NSE Vol: 55.32 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
JFL Life
Kabra Drugs
Ajooni Biotech
ANG Lifesciences
Mangalam Drugs
Rajnish Wellness
Vasundhara Rasy.
Biofil Chemicals
Bharat Immunolog
Chandra Bhagat
Murae Organisor
Why is Kabra Drugs Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.36%
  • Poor long term growth as Net Sales has grown by an annual rate of 9,274.00% and Operating profit at 404.05% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at 0.22 times
2
Stock is technically in a Mildly Bearish range
  • The stocks Bollinger Band and KST technical factors are also Bearish
3
Underperformed the market in the last 1 year
  • Even though the market (BSE500) has generated returns of 0.37% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -27.50% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kabra Drugs for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Kabra Drugs
-27.5%
-0.50
55.45%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
9,274.00%
EBIT Growth (5y)
404.05%
EBIT to Interest (avg)
0.60
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
1.17
Tax Ratio
13.29%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-19.25%
ROE (avg)
3.35%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
6
Industry P/E
40
Price to Book Value
1.33
EV to EBIT
8.24
EV to EBITDA
8.13
EV to Capital Employed
1.35
EV to Sales
0.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
16.32%
ROE (Latest)
14.74%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company
NET SALES(Latest six months)

At Rs 78.17 cr has Grown at 190.49%

PAT(Latest six months)

At Rs 4.11 cr has Grown at 207.07%

-4What is not working for the Company
OPERATING CF(Y)

Lowest at Rs -9.46 Cr

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 1.73 cr

Loading Valuation Snapshot...
Here's what is working for Kabra Drugs
Net Sales - Latest six months
At Rs 78.17 cr has Grown at 190.49%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (Rs Cr)

Profit After Tax (PAT) - Latest six months
At Rs 4.11 cr has Grown at 207.07%
Year on Year (YoY)
MOJO Watch
PAT trend is very positive

PAT (Rs Cr)

Here's what is not working for Kabra Drugs
Operating Cash Flow - Annually
Lowest at Rs -9.46 Cr and Fallen
each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (Rs Cr)

Cash and Cash Equivalents - Half Yearly
Lowest at Rs 1.73 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents